探索可溶性瓜尼环酶刺激剂和激活剂在心力衰竭中的潜力
Olga Gawrys1, Petr Kala2, Michal Šnorek3
1Experimental Medicine Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Biochemical pharmacology
|September 23, 2025
概括
可溶性瓜尼利基环酶 (sGC) 刺激剂和激活剂通过增强循环瓜诺辛单酸 (cGMP) 信号传递,显示出治疗心力衰竭 (HF) 的前景. 虽然它们在减少喷射分数 (HFrEF) 的高频中有效,但它们在保持喷射分数 (HFpEF) 的高频中所起的作用需要进一步研究.
科学领域:
- 心血管药理学心血管药理学
- 医学生物化学 医学生物化学
- 翻译医学是一种翻译医学.
背景情况:
- 尽管治疗方面取得了进展,但心力衰竭 (HF) 仍然是导致发病和死亡的重要原因.
- 循环瓜诺辛3',5'-单酸盐 (cGMP) 信号传导的缺陷与心血管疾病 (如高血压,肺高血压和病) 有关.
- 氧化物 (NO) -可溶性瓜尼利基环酶 (sGC) -cGMP通路对于心血管平衡至关重要.
研究的目的:
- 审查NO-sGC-cGMP信号在心血管和心脏功能中的证据.
- 专注于各种HF亚型中的sGC刺激剂和激活剂的临床前和临床数据.
- 评估向NO-sGC-cGMP途径在HF和相关心脏脏疾病中的治疗潜力.
主要方法:
- 临床前研究和临床试验的文献综述.
- 对sGC刺激剂 (例如,riociguat, vericiguat) 和sGC激活剂的数据分析.
- 检查减少喷射率 (HFrEF) 的HF和保存喷射率 (HFpEF) 的HF的证据.
主要成果:
- sGC刺激剂在HFrEF的临床试验中显示出有希望的结果.
- sGC激活器正在研究慢性脏疾病.
- 目前对HFpEF有效性的证据缺乏或不确.
结论:
- NO-sGC-cGMP通路调节为高频率提供了治疗潜力.
- sGC刺激剂和激活剂代表了心血管药理学的重大进步.
- 需要进一步的研究来阐明机制,并优化对HF和心脏病的临床实施.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
942
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
01:26Heart Failure Drugs: Inotropic Agents
1.3K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.3K
01:30Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.9K
01:29Heart Failure II: Pathophysiology
734
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
734
01:22Heart Failure Drugs: β-Blockers
772
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
772